title: Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry.
abstract: In a number of human diseases of chronic inflammatory or autoimmune character, immunoglobulin molecules display aberrant glycosylation patterns of N- or O-linked glycans. In IgA nephropathy, IgA1 molecules with incompletely galactosylated O-linked glycans in the hinge region (HR) are present in mesangial immunodeposits and in circulating immune complexes. It is not known whether the Gal deficiency in IgA1 proteins occurs randomly or preferentially at specific sites. To develop experimental approaches to address this question, the synthetic IgA1 hinge region and hinge region from a naturally Gal-deficient IgA1 myeloma protein have been analyzed by 9.4 tesla Fourier transform-ion cyclotron resonance mass spectrometry. Fourier transform-ion cyclotron resonance mass spectrometry offers two complementary fragmentation techniques for analysis of protein glycosylation by tandem mass spectrometry. Infrared multiphoton dissociation of isolated myeloma IgA1 hinge region peptides confirms the amino acid sequence of the de-glycosylated peptide and positively identifies a series of fragments differing in O-glycosylation. To localize sites of O-glycan attachment, synthetic IgA1 HR glycopeptides and HR from a naturally Gal-deficient polymeric IgA1 myeloma protein were analyzed by electron capture dissociation and activated ion-electron capture dissociation. Multiple sites of O-glycan attachment (including sites of Gal deficiency) in myeloma IgA1 HR glycoforms were identified (in all but one case uniquely). These results represent the first direct identification of multiple sites of O-glycan attachment in IgA1 hinge region by mass spectrometry, thereby enabling future characterization at the molecular level of aberrant glycosylation of IgA1 in diseases such as IgA nephropathy.
authors.affiliation: National High Magnetic Field Laboratory, Florida State University, Tallahassee, Florida 32310-4005, USA.
authors.forename: Matthew B
authors.initials: MB
authors.lastname: Renfrow
authors.forename: Helen J
authors.initials: HJ
authors.lastname: Cooper
authors.forename: Milan
authors.initials: M
authors.lastname: Tomana
authors.forename: Rose
authors.initials: R
authors.lastname: Kulhavy
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Hiki
authors.forename: Kazunori
authors.initials: K
authors.lastname: Toma
authors.forename: Mark R
authors.initials: MR
authors.lastname: Emmett
authors.forename: Jiri
authors.initials: J
authors.lastname: Mestecky
authors.forename: Alan G
authors.initials: AG
authors.lastname: Marshall
authors.forename: Jan
authors.initials: J
authors.lastname: Novak
mesh_terms: D000595:Amino Acid Sequence; D000596:Amino Acids / Q000737:chemistry; D049109:Cell Proliferation; D017357:Cyclotrons; D004583:Electrons; D005583:Fourier Analysis; D005920:Glomerular Mesangium / Q000378:metabolism; D005922:Glomerulonephritis, IGA / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D007070:Immunoglobulin A / Q000737:chemistry* / Q000378:metabolism; D007477:Ions; D013058:Mass Spectrometry; D008969:Molecular Sequence Data; D009005:Monosaccharides / Q000737:chemistry; D009101:Multiple Myeloma / Q000378:metabolism; D010455:Peptides / Q000737:chemistry; D017785:Photons; D011134:Polysaccharides / Q000737:chemistry; D021241:Spectrometry, Mass, Electrospray Ionization; D014357:Trypsin / Q000494:pharmacology
chemical_list: D000596:Amino Acids; D007070:Immunoglobulin A; D007477:Ions; D009005:Monosaccharides; D010455:Peptides; D011134:Polysaccharides; D014357:Trypsin